METHODS	S0008 ( S0008 : Chemotherapy Plus Biological Therapy in Treating Patients With Melanoma ) was an Intergroup phase III trial that enrolled high-risk patients ( stage IIIA-N2a through IIIC-N3 ) , randomly assigning them to receive either HDI or biochemotherapy consisting of dacarbazine , cisplatin , vinblastine , interleukin-2 , IFN alfa-2b ( IFN -- 2b ) and granulocyte colony-stimulating factor given every 21 days for three cycles .\